Dynasil Corp Schedules Fiscal 2017 Second Quarter Financial Results Conference Call:
Right. But after every buy and lack of more bid support someone always brings ask back down for 100 shares. Wondering why... they least news can send DYSL over 2 $ now. Looking forward to the cc.
After much cost averaging, on the right side of the trade and holding because I think the contracts research and optics are growing and I still don't think much value is assigned to biomedical in the stock price. Any positive XCede trial news and this breaks out to new 52-wk highs. We have 2 reputable investors/partners in Mayo Clinic and Cook who know a whole lot more about XCede than we do and they apparently like the numbers. Last contact w/co., was told the Xcede trial is "on schedule" for dosing patients this year. 3 of 9 required toxicology studies are underway along with QC details and other necessary steps by Cook Biotech. They are happy with their progress. So am I, after Xcede sitting on the shelf so long; it's progress. IMO the lack of progress til now is why the market up to this point has seen XCede as dead money. Any clinical progress with it will increase investor interest and add value to that subsidiary.
Some complain they are not shareholder-friendly, but my emails always were answered.
Lack of investor awareness, past performance including the drag of XCede, may be contributing factors. Also some have stated that management doesn't seem to be able to sell the story to Wall Street.
On that note, I think investor sentiment is turning around some. We got a partner for XCede to start the pre-clinicals, so positive progress will add value to biomedical and imo share price. Optics is growing. and current administration looks to be interested in increasing defense spending, which is good for RMD. Also, one of Sulick's CC responses seemed to allude that the major holders may be open to selling parts of the company since they own almost half of DYSL and are getting old. He said the board would meet in May, so who knows we may see a buyout or partial asset sale down the road.
It's crazy DYSL is still trading at 1,4$ with all the good news and all the proces going on. This will not stay at these pps much longer. Should trade at least between 3$ - 5$ for now.
$750k NASA Contract, 4/12:
$500k DHS Contract, 3/31:
Definitely looking up here. Positive Xcede clinical trial news will add a lot of value to the company and boost the share price imo
Some late buying. Nice run but company still undervalued. We should at least be trading between $1.50-2.
Great stuff... pr tomorrow. Nice start of the week. Tnx. D
Crystals grown in space. Pretty cool stuff. Can see the obvious application for DHS and other government. Maybe this is the turnaround we need to begin trading a bit closer towards our valuation
RMD working on Perovskite Solar Cell technology. Take a look. This new technology will be HUGE.
This traded much higher before optics growth, the Cook partnership, or any X-Cede progress whatsoever. It's trading near book. It will take a major event to take this higher, like a buyout or clinical trial news.
This company is not good at keeping communication with shareholders. We want updates, shareholder letters, new platforms, new customers.
Cool stuff indeed. We should likely see RMD grant news again this quarter or next. Glad to see someone else post here with some related content.
Indeed, news would be very welcome. Where is the ecommerce site. Should be pr'd end of Feb.
Seems to be grinding higher. Not too many sellers in the teens. Chart showing signs of reversal, but volume is unconvincing. Grant news or new developments would be nice.
Com on Mr Sulick! Where is the ecommerce site??? Waiting for almost 3 years now... all stocks are making new hights and DYSL not moving a dime... DYSL might be worth 4 Dollar as you say, but we are still trading at 1,2$... please give us at least something.
Same here... E-commerce should be up and running in Feb 2017 so that or we can expect soon. But much more happening imo. We'll soon find out.
Well I 100% agree on that. Imo I think some traders sold on that news, still imo i think they are wrong. I don't see why the insiders would dilute all the shares they are holding. Havd
declaes I agree, they can raise without dilution.
I was just point out to something that could have triggered the heavy sell orders. so just trying to give na explanation to the big down day when result were released.
Now let's hope something exciting gets out from the meeting.
Fabius, the company is different because they already have employees and is already operating, but as I understand, they are in the same business as Xcede.
"We don't have the money to do it, we would have to raise the money" But that doesn't necessarily mean they will do it via diluting. Hope to hear something more about this deal on the annual meeting today.
We will have a special section for Xcede there...should be very interesting
from my understanding it is not for Xcede, but it is another potential acquisition: see below
from the last CC
"The other thing I mentioned in my prepared remarks is that we are looking at a potential acquisition that could assist with Xcede. It had -- they have a number of employees already, it's an operating company as oppose to a development stage company, and so it's significantly different than Xcede is at the moment.
But it could really jump-start that business, if we can pull it off. We don't have the money to do it, we would have to raise the money. We're not real clear on what that structure would look like yet, there's a lot of imponderables about this thing at the moment. But the first step is, if we have done some due diligence we visited the company a few times, we believe that it's an acquisition that is worth doing, if we -- if it's accepted. And -- but there's a lot of time, distance and work that has to be done before we get to that plan. And even if we are now -- if our LOI is accepted it's not likely that we would close this transaction for about six months, would be our guess. But it does give us yet another option in the value proposition of Xcede so."
Fabius, why do you think DYSL will raise money via diluting to finance Xcede. There are some other potential paths, that would be much better for shareholders. Don't forget insiders are holding a lot of shares here. I think DYSL will surge for better options and do have other solutions in mind. Try to read between the lines on the CC.
I agree, but we are talking about speculators and not investors.
As i said before offering shares to buy a company is not dilluting. You get something for those shares that has a value and generate income. The value of the company goes up. If investors don't understand that, it's better they stop investing. It's not like you dillute to pay the bills or pay your people.
They push the price down, waiting for possible dilution; then, when the price looks particularly cheap (new shares issue or not) then they jump in.
tiny caps are played until the company is able to dissolve uncertainty (whatever it is)
Fingers crossed for the weeks to come
I think you are right. But if you have something agains investing money in a company to make huge profits..??? I don't understand what those people are doing in the stockmarket...
I believe the statement I outlined about the CC, where they say they have no money for the potential M&A is the reason we may have even lower prices.
I do agree there is some huge potential development, but as far as the masrket sees the potential for dilution...
Anyway if it goes down I am ready to buy more.
Dynasil specializes in the development and manufacture of detection, sensing and analysis technology, precision instruments and optical components. Our products target high-growth applications in the homeland security, medical and industrial markets.
Technology leadership and innovation drives our economy and fuels America’s competitiveness in the global market. It is what pushes us to strive and grow. The same is true of our organization. One of the hallmarks of Dynasil is its strong business model built on innovating science, research and technology, and its successful track record of bringing technology to market.
COMPANY CONTACT INFORMATION:
TRADING EXCHANGE LISTING: NASDAQ Dynasil Corporation of America (NASDAQ: DYSL)
YEAR OF INCORPORATION: 1960
Through a series of acquisitions, Dynasil has evolved from a single-product line optics company providing synthetic fused silica to an emerging-growth company focused on commercializing its own products, patenting its own innovations and advancing its own technologies. Our revenue has increased from $2 million in FY 2004 to nearly $43 million in FY 2013.
|Peter Sulick |
Chairman of the Board, Interim Chief Executive Officer and President
|Thomas C. Leonard |
Chief Financial Officer
|Patricia Kehe |
NUMBER Of ELOYEES 222 (as of 01/01/2014)
SEC REPORTING STATUS: Fully Reporting
FISCAL YEAR END: 09/30
Authorized Shares: 25,000,000 (as of 01/01/2014)
Shares Outstanding: 15,020,000 (as of 01/01/2014)
Float: 8,310,000 Shares (as of 01/01/2014)
ONE YEAR STOCK PRICE & VOLUME CHART:
DISCLAIMER: Nothing in the contents transmitted on this board should be construed as an investment advisory, nor should it be used to make investment decisions. There is no express or implied solicitation to buy or sell securities. The author(s) may have positions in the stocks or financial relationships with the company or companies discussed and may trade in the stocks mentioned. Readers are advised to conduct their own due diligence prior to considering buying or selling any stock. All information should be considered for information purposes only. No stock exchange has approved or disapproved of the information contained herein.
http://ih.advfn.com/p.php?pid=nmona&article=62166372 (Q2 results)
http://biz.yahoo.com/e/140924/dysl8-k.html (Change in Directors or Principal Officers)
http://finance.yahoo.com/news/dynasil-announces-completion-xcede-technologies-142000369.html (Dynasil Announces Completion of Xcede Technologies' $2 Million Convertible Note Financing)